Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Ceska

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
JAMA Cardiology|May 23, 2019
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER TrialSabina A Murphy, Terje R Pedersen, Zbigniew A Gaciong, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Global Heart|November 17, 2025
The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!Maciej Banach, Zlatko Fras, Dan Gaita, et al.
Lancet (London, England)|September 2, 2017
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialRobert P Giugliano, Terje R Pedersen, Jeong-Gun Park, et al.
Diabetes & Vascular Disease Research|October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patientJean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
Expert Opinion on Drug Safety|April 25, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
GMS Health Innovation and Technologies|October 31, 2022
The time is now: Achieving FH paediatric screening across Europe - The Prague DeclarationNicole Bedlington, Marianne Abifadel, Birgit Beger, et al.
Archives of Medical Science : AMS|April 11, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
Drugs|November 4, 2024
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)Maciej Banach, Željko Reiner, Stanisław Surma, et al.
Cardiovascular Diabetology|June 6, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) FoundationJean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
JAMA Cardiology|May 23, 2019
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER TrialSabina A Murphy, Terje R Pedersen, Zbigniew A Gaciong, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Global Heart|November 17, 2025
The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!Maciej Banach, Zlatko Fras, Dan Gaita, et al.
Lancet (London, England)|September 2, 2017
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialRobert P Giugliano, Terje R Pedersen, Jeong-Gun Park, et al.
Diabetes & Vascular Disease Research|October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patientJean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
Expert Opinion on Drug Safety|April 25, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
GMS Health Innovation and Technologies|October 31, 2022
The time is now: Achieving FH paediatric screening across Europe - The Prague DeclarationNicole Bedlington, Marianne Abifadel, Birgit Beger, et al.
Archives of Medical Science : AMS|April 11, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
Drugs|November 4, 2024
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)Maciej Banach, Željko Reiner, Stanisław Surma, et al.
Cardiovascular Diabetology|June 6, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) FoundationJean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, et al.
Pageof 6